${\beta}_2$-촉진제 사용전후에 따른 만성폐쇄성폐질환/천식 환자의 음성 연구

A Study about Voice of Patients with Chronic Obstructive Pulmonary Disease/Asthma before & after ${\beta}_2$-agonist

  • 강영애 (충남대학교 언어병리학과) ;
  • 김세훈 (건양대학교 의과대학 생리학) ;
  • 정성수 (충남대학교병원 호흡기내과) ;
  • 이태용 (충남대학교 의과대학 예방의학과) ;
  • 성철재 (충남대학교 인문대학 언어학과)
  • 투고 : 2010.04.21
  • 심사 : 2010.06.22
  • 발행 : 2010.06.30

초록

An inhaled salbutamol and salmeterol for chronic obstructive pulmonary disease(COPD) and asthma have been used worldwidely. But there has been few study about the voice change evoked from the post-medicine effect. To evaluate the voice influenced of short-acting and long-acting ${\beta}_2$-agonists, two experiments were carried out: one was salbutamol experiment 1 with eight patients, the other was salmeterol experiment 2 with six patients. Experiment 1 was made of two stages: premedication & postmedication. Experiment 2 was four stages: stageI was premedication, stageII was postmedication & pregaggling, stageIII was postmedication & postgaggling(100 ml with water), and stageIV was postmedication & 30 minutes later. Measured parameters were F0, F0_SD, Jitter_rap, Shimmer_apq11, HNR, BW(1, 2, 3), Intensity, and H1-H2. The mean data collected from 3 repetitions each was statistically analyzed by Wilcoxon signed rank test for experiment 1 and repeated measures ANOVA for experiment 2. In experiment 1, significant differences were found in the Jitter_rap(Z= -2.10, p=0.036). The findings indicated that the postmedicated voice was worse than premedicated voice. In experiment 2, there wasn't significant difference, but values of parameters related to voice quality(Jitter_rap, Shimmer_apq11, HNR, and H1-H2) showed changes toward stageⅣ, that is, the voice quality was worse under medication.

키워드